MaxCyte, Inc.

22 Firstfield Road, Suite 110
Gaithersburg
Maryland
20878
United States

Tel: 1-301-944-1700
Fax: 1-301-944-1703

About MaxCyte, Inc.

We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.

This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell-engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.

We are also developing novel CARMA cellular therapies for our own pipeline with our first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s novel proprietary technology for development of human mRNA-based cellular therapies to treat a broad range of diseases.

Stock Exchange: Alternative Investment Market

Stock Symbol: MXCT

At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use, more cost-effectively and with lowered risk. We have developed and commercialized MaxCyte Scalable Transfection Systems for high-performance delivery of biomolecules using Flow Electroporation ® Technology, a proprietary cell-engineering technology designed to meet the stringent demands of clinical use – namely, the ability to safely and reproducibly modify primary human cells with high efficiency, low cytotoxicity, and at the scale required to treat patients.

MaxCyte, Inc.

About MaxCyte, Inc.

142 articles with MaxCyte, Inc.

The MaxCyte, Inc. VLX Large Scale Transfection System for Protein and Antibody Production is Launched at PepTalk 2012

MaxCyte, Inc. Highlights Innovations in Scalable, High-Throughput Transfection for Cell-Based Assays & Protein Production at the SBS Annual Meeting in Orlando, FL, Booth #812

MaxCyte, Inc. STX(TM) Scalable Transfection System Demonstrated to Improve Drug Discovery Screening at the LabAutomation 2011 Conference

CCS Cell Culture Service GmbH Acquires the MaxCyte, Inc. STX(TM) Scalable Transfection System for Cell Line Development

MaxCyte, Inc. STXpert Users Explain How to Fast Track Cell Based Assay Development at the SBS Annual Meeting in Phoenix, Booth 342

MaxCyte, Inc. Announces Expansion of License with Medinet Co, Ltd

Improved Optimization and Development of Ion Channels for Cell-Based Assays MaxCyte, Inc. Webinar with Case Studies from BioFocus DPI

MaxCyte, Inc. Webinar with Case Studies from ChanTest, Inc.: Improving Large Scale GPCR and Ion Channel Assays

MaxCyte, Inc. to present on development of novel tumor-targeted enhanced potency T cell immunotherapy at the 15th Annual Meeting of the International Society of Cellular Therapy (ISCT)

MaxCyte, Inc. GT Flow Transfection System Now Available to Academic and Clinical Investigators

MaxCyte, Inc. STX Scalable Transfection System for Cell-Based Assays in Drug Discovery: Screening Data to Be Presented at the 15th Annual SBS Meeting in Lille, France

MaxCyte, Inc. Presents Membrane Protein Expression Data at the Biophysical Society’s Ion Channel Meeting

MaxCyte, Inc. Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies

MaxCyte, Inc. Release: The MaxCyte(R) STX(TM) Scalable Transfection System to be Presented at the Rapid Fire Innovation Session at LabAutomation2009

MaxCyte, Inc. Presents a Panel Discussion With Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery

MaxCyte, Inc. to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology

MaxCyte, Inc. STX(R) Scalable Transfection System Launched in Europe at SMi's Cell-Based Assays Conference in London

MaxCyte, Inc. Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery

The MaxCyte, Inc. STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays

MaxCyte, Inc. Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting